The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EDAP | -37.59% | -58.68% | -16.2% | -79% |
| S&P | +18.33% | +108.18% | +15.79% | +628% |
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $18.20M | 7.0% |
| Gross Profit | $7.74M | 21.4% |
| Gross Margin | 42.52% | 5.0% |
| Market Cap | $61.70M | -69.4% |
| Market Cap / Employee | $0.20M | 0.0% |
| Employees | 310 | 1.0% |
| Net Income | -$6.35M | 3.8% |
| EBITDA | -$6.62M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2024 | YOY Change | |
|---|---|---|
| Net Cash | $30.90M | -35.7% |
| Accounts Receivable | $21.75M | 11.4% |
| Inventory | 18.2 | -5.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.15M | -16.1% |
| Short Term Debt | $7.37M | 286.2% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -22.13% | 0.0% |
| Return On Invested Capital | -17.30% | -9.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.26M | 16.4% |
| Operating Free Cash Flow | -$4.66M | 30.2% |
| Metric | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.53 | 1.61 | 1.73 | 1.66 | -61.78% |
| Price to Sales | 3.00 | 4.15 | 3.02 | - | |
| Price to Tangible Book Value | 3.70 | 1.69 | 1.89 | 1.78 | -61.43% |
| Enterprise Value to EBITDA | -17.66 | -11.18 | -8.03 | - | |
| Return on Equity | -32.8% | -30.4% | -35.4% | - | |
| Total Debt | $5.66M | $14.41M | $9.81M | $10.52M | 42.39% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
